Effect of risedronate on osteocyte viability and bone turnover in paired iliac bone biopsies from early postmenopausal women.
It is unclear whether standard clinical doses of risedronate affect osteocyte viability. This study examined osteocyte viability and bone remodeling rate in early postmenopausal women (1-5 years after menopause) who were treated with a standard clinical dose of risedronate (5 mg/day, orally) for 1 year. Paired transiliac bone biopsies were obtained from 19 postmenopausal women at baseline and after 1-year treatment with placebo (n = 8, mean age 52.9 ± 3.4 years) or risedronate 5 mg/day (n = 11, mean age 52.5 ± 3.4 years). In these samples, we measured osteocyte- and bone remodeling-related variables in trabecular bone. In both the placebo and risedronate groups, empty lacunae were significantly decreased after 1-year treatment compared to baseline. There were no significant differences in osteocyte-related variables between placebo and risedronate. Risedronate significantly reduced bone-remodeling indices including mineralizing surface (MS/BS), bone formation rate (BFR/BS), and activation frequency (Ac.f). Risedronate treatment caused significantly lower MS/BS and Ac.f than placebo administration. In conclusion, risedronate 5 mg/day effectively inhibited bone remodeling but did not significantly reduce osteocyte viability in trabecular bone.
Qiu
S
S
Bone and Mineral Research Laboratory, Henry Ford Hospital, E&R Building 7071, 2799 W Grand Blvd., Detroit, MI 48202, USA. qiu@bjc.hfh.edu
Phipps
R J
RJ
Ebetino
F H
FH
Palnitkar
S
S
Sudhaker Rao
D
D
D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002470:Cell Survival / Q000187:drug effects / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D012968:Etidronic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D006801:Humans; D007085:Ilium / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D008875:Middle Aged; D010011:Osteocytes / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000503:physiopathology; D000068296:Risedronic Acid; D016896:Treatment Outcome
D050071:Bone Density Conservation Agents; D000068296:Risedronic Acid; D012968:Etidronic Acid